Abstract:Background: Elevated extracellular matrix (ECM) accumulation is a major contributing factor to the pathogenesis of fibrotic diseases. Recent studies have indicated that N6-methyladenosine (m6A) RNA modification plays a pivotal role in modulating RNA stability and contribute to the initiation of various pathological conditions. Howbeit, the precise mechanism by which m6A influences ECM deposition remains unclear. Methods: In this study, we used hypertrophic scars (HTSs) as a paradigm to investigate ECM-related diseases. We focused on the role of ALKBH5-mediated m6A demethylation within the pathological progression of HTSs and examined its correlation with clinical stages. The effects of ALKBH5 ablation on ECM components were studied both in vivo and in vitro. Downstream targets of ALKBH5, along with their underlying mechanisms, were identified using integrated high-throughput analysis, RNA-binding protein immunoprecipitation and RNA pull-down assays. Furthermore, the therapeutic potential of exogenous ALKBH5 overexpression was evaluated in fibrotic scar models. Results: ALKBH5 was decreased in fibroblasts derived from HTS lesions and was negatively correlated with their clinical stages. Importantly, ablation of ALKBH5 promoted the expression of COL3A1, COL1A1, and ELN, leading to pathological deposition and reconstruction of the ECM both in vivo and in vitro. From a therapeutic perspective, the exogenous overexpression of ALKBH5 significantly inhibited abnormal collagen deposition in fibrotic scar models. As determined by integrated high-throughput analysis, key ECM components including COL3A1, COL1A1, and ELN are direct downstream targets of ALKBH5. By means of its mechanism, ALKBH5 inhibits the expression of COL3A1, COL1A1, and ELN by removing m6A from mRNAs, thereby decreasing their stability in a YTHDF1-dependent manner. Conclusions: Our study identified ALKBH5 as an endogenous suppressor of pathological ECM deposition, contributing to the development of a reprogrammed m6A-targeted therapy for HTSs.

Potential Genetic Therapies Based on M6a Methylation for Skin Regeneration: Wound Healing and Scars/keloids

Unraveling the landscape of m6A RNA methylation in wound healing and scars

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

M6a-Binding Proteins: the Emerging Crucial Performers in Epigenetics

Comprehensive Modular Analyses of Scar Subtypes Illuminate Underlying Molecular Mechanisms and Potential Therapeutic Targets.

RNA N6-methyladenosine methylation and skin diseases

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The Potential Value of M6a RNA Methylation in the Development of Cancers Focus on Malignant Glioma

ALKBH5-mediated M6a Demethylation Fuels Cutaneous Wound Re-Epithelialization by Enhancing PELI2 Mrna Stability

Epitranscriptomic m6A regulation following spinal cord injury

The m6A RNA Modification Modulates Gene Expression and Fibrosis-Related Pathways in Hypertrophic Scar

Landscape of the epigenetic regulation in wound healing

Severe Burn Injury Significantly Alters the Gene Expression and M6a Methylation Tagging of Mrnas and Lncrnas in Human Skin

Causes and consequences of epigenetic regulation in wound healing.

The role of m6A in angiogenesis and vascular diseases

N6-methyladenosine functions and its role in skin cancer

m6A modification in non-coding RNAs: Mechanisms and potential therapeutic implications in fibrosis

ALKBH5-mediated m6A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis

Epigenetic modification mechanisms involved in keloid: current status and prospect

N<SUP>6</SUP>-methyladenosine modification of lncRNA <i>Pvt1</i> governs epidermal stemness

Alteration of the m(6)A methylation landscape in a mouse model of scleroderma